Indivior (INDV) said Wednesday that a clinical trial has found a rapid induction approach using its Sublocade treatment was well tolerated and led to higher treatment retention rates than standard induction among people with opioid use disorder, especially those using fentanyl.

The company said the study compared rapid induction

-- administering a single 4 mg oral buprenorphine dose followed by a same-day Sublocade injection -- with the standard method, which requires at least seven days of oral buprenorphine dose adjustments before the first injection.

Participants who began with the rapid approach were more likely to return for their second injection, the company said.

The trial also showed that administering the second injection just one week after the first was safe and well tolerated in both groups, supporting a more flexible treatment approach, Indivior said.

Shares of the company were up nearly 2% in recent Wednesday premarket activity.